Evolus Inc EOLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EOLS is a good fit for your portfolio.
News
-
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
-
Evolus Announces Results from European Head-to-Head Filler Trial
-
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Trading Information
- Previous Close Price
- $11.71
- Day Range
- $11.66–11.97
- 52-Week Range
- $7.08–15.42
- Bid/Ask
- $11.78 / $11.80
- Market Cap
- $725.06 Mil
- Volume/Avg
- 148,766 / 589,186
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.30
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 273
- Website
- https://www.evolus.com
Comparables
Valuation
|
Metric
|
EOLS
|
SIBN
|
AGL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.68 | 3.17 |
Price/Sales | 3.30 | 4.23 | 0.49 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EOLS
|
SIBN
|
AGL
|
|---|---|---|---|
Quick Ratio | 1.93 | 8.01 | 1.46 |
Current Ratio | 2.33 | 9.01 | 1.51 |
Interest Coverage | −3.51 | −13.52 | −28.21 |
Quick Ratio
EOLS
SIBN
AGL
Profitability
|
Metric
|
EOLS
|
SIBN
|
AGL
|
|---|---|---|---|
Return on Assets (Normalized) | −28.17% | −8.97% | −5.02% |
Return on Equity (Normalized) | — | −12.61% | −11.33% |
Return on Invested Capital (Normalized) | −42.52% | −11.78% | −10.18% |
Return on Assets
EOLS
SIBN
AGL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Wcgmjcxjhj | Kqht | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Vwkbwxbwd | Zkhpdmc | $68.4 Bil | |
HLN
| Haleon PLC ADR | Nqqnjzgk | Gczr | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Pvksgzgr | Pghmy | $14.5 Bil | |
VTRS
| Viatris Inc | Vncmvkjx | Sxhw | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qlsglkd | Kvvm | $12.0 Bil | |
CTLT
| Catalent Inc | Mchjvdpq | Ssjyk | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Wgxvxjnd | Cqtzq | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Vjbgmwqxz | Mcrzx | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qpnlndl | Spxlc | $3.5 Bil |